25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Arcturus Therapeutics Holdings Inc
Buy, Hold or Sell?

Let's analyze Arcturus Therapeutics Holdings Inc together

I guess you are interested in Arcturus Therapeutics Holdings Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Arcturus Therapeutics Holdings Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Arcturus Therapeutics Holdings Inc

I send you an email if I find something interesting about Arcturus Therapeutics Holdings Inc.

1. Quick Overview

1.1. Quick analysis of Arcturus Therapeutics Holdings Inc (30 sec.)










1.2. What can you expect buying and holding a share of Arcturus Therapeutics Holdings Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$9.67
Expected worth in 1 year
$9.00
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-0.67
Return On Investment
-3.6%

For what price can you sell your share?

Current Price per Share
$18.64
Expected price per share
$14.21 - $25.54
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Arcturus Therapeutics Holdings Inc (5 min.)




Live pricePrice per Share (EOD)
$18.64
Intrinsic Value Per Share
$-17.95 - $-18.72
Total Value Per Share
$-8.28 - $-9.05

2.2. Growth of Arcturus Therapeutics Holdings Inc (5 min.)




Is Arcturus Therapeutics Holdings Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$261.8m$291.1m-$25.4m-9.6%

How much money is Arcturus Therapeutics Holdings Inc making?

Current yearPrevious yearGrowGrow %
Making money-$12.1m$24.8m-$37m-303.6%
Net Profit Margin-35.2%-112.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Arcturus Therapeutics Holdings Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#219 / 950

Most Revenue
#161 / 950

Most Profit
#603 / 950

Most Efficient
#377 / 950
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Arcturus Therapeutics Holdings Inc?

Welcome investor! Arcturus Therapeutics Holdings Inc's management wants to use your money to grow the business. In return you get a share of Arcturus Therapeutics Holdings Inc.

First you should know what it really means to hold a share of Arcturus Therapeutics Holdings Inc. And how you can make/lose money.

Speculation

The Price per Share of Arcturus Therapeutics Holdings Inc is $18.64. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Arcturus Therapeutics Holdings Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Arcturus Therapeutics Holdings Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $9.67. Based on the TTM, the Book Value Change Per Share is $-0.17 per quarter. Based on the YOY, the Book Value Change Per Share is $1.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Arcturus Therapeutics Holdings Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.140.8%-0.45-2.4%-0.65-3.5%-0.95-5.1%-0.56-3.0%
Usd Book Value Change Per Share0.120.7%-0.17-0.9%1.246.7%0.422.2%0.221.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.120.7%-0.17-0.9%1.246.7%0.422.2%0.221.2%
Usd Price Per Share23.21-28.22-23.79-29.15-17.23-
Price to Earnings Ratio41.17--0.46--3.34--5.92--8.86-
Price-to-Total Gains Ratio191.50--136.29--34.61--44.54--36.66-
Price to Book Ratio2.40-2.87-2.22-4.96-5.75-
Price-to-Total Gains Ratio191.50--136.29--34.61--44.54--36.66-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share18.64
Number of shares53
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.170.42
Usd Total Gains Per Share-0.170.42
Gains per Quarter (53 shares)-8.9022.11
Gains per Year (53 shares)-35.6088.43
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-36-4608878
20-71-820177166
30-107-1180265254
40-142-1540354342
50-178-1900442430
60-214-2260531518
70-249-2620619606
80-285-2980707694
90-320-3340796782
100-356-3700884870

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%3.037.00.07.5%3.045.00.06.3%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%6.014.00.030.0%10.028.02.025.0%12.033.03.025.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.048.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%6.014.00.030.0%10.028.02.025.0%12.033.03.025.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Arcturus Therapeutics Holdings Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.121-0.168+239%1.240-90%0.417-71%0.218-44%
Book Value Per Share--9.6679.810-1%10.743-10%8.617+12%4.962+95%
Current Ratio--4.7634.129+15%4.159+15%4.911-3%7.954-40%
Debt To Asset Ratio--0.2940.337-13%0.357-18%0.391-25%0.333-12%
Debt To Equity Ratio--0.4150.512-19%0.560-26%0.792-48%0.819-49%
Dividend Per Share----0%-0%-0%-0%
Eps--0.141-0.450+419%-0.652+563%-0.949+773%-0.563+500%
Free Cash Flow Per Share---0.867-0.562-35%1.265-169%-0.456-47%-0.290-67%
Free Cash Flow To Equity Per Share---0.840-0.679-19%1.195-170%0.409-306%0.274-407%
Gross Profit Margin--1.0001.037-4%1.0000%1.007-1%1.0040%
Intrinsic Value_10Y_max---18.719--------
Intrinsic Value_10Y_min---17.946--------
Intrinsic Value_1Y_max---1.267--------
Intrinsic Value_1Y_min---1.332--------
Intrinsic Value_3Y_max---4.271--------
Intrinsic Value_3Y_min---4.429--------
Intrinsic Value_5Y_max---7.834--------
Intrinsic Value_5Y_min---7.971--------
Market Cap504909136.000-25%628698554.000764270991.000-18%644778384.000-2%789603819.100-20%466705412.850+35%
Net Profit Margin--0.092-0.352+485%-1.125+1327%-6.827+7552%-3.795+4242%
Operating Margin----0.3150%-1.3430%-6.8380%-3.8030%
Operating Ratio--1.2581.369-8%3.901-68%13.716-91%7.800-84%
Pb Ratio1.928-25%2.4012.871-16%2.218+8%4.958-52%5.753-58%
Pe Ratio33.061-25%41.167-0.461+101%-3.335+108%-5.920+114%-8.862+122%
Price Per Share18.640-25%23.21028.215-18%23.790-2%29.148-20%17.228+35%
Price To Free Cash Flow Ratio-5.373+20%-6.690-51.533+670%-1.262-81%-18.343+174%-13.132+96%
Price To Total Gains Ratio153.795-25%191.501-136.291+171%-34.611+118%-44.540+123%-36.659+119%
Quick Ratio--3.8493.727+3%3.844+0%4.728-19%11.769-67%
Return On Assets--0.010-0.029+386%0.053-80%-0.059+668%-0.086+930%
Return On Equity--0.015-0.046+416%0.087-83%-0.123+947%-0.164+1226%
Total Gains Per Share--0.121-0.168+239%1.240-90%0.417-71%0.218-44%
Usd Book Value--261866000.000265733500.000-1%291199250.000-10%233441800.000+12%134419150.000+95%
Usd Book Value Change Per Share--0.121-0.168+239%1.240-90%0.417-71%0.218-44%
Usd Book Value Per Share--9.6679.810-1%10.743-10%8.617+12%4.962+95%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.141-0.450+419%-0.652+563%-0.949+773%-0.563+500%
Usd Free Cash Flow---23493212.000-15211186.750-35%34239000.000-169%-12348937.350-47%-7870193.675-67%
Usd Free Cash Flow Per Share---0.867-0.562-35%1.265-169%-0.456-47%-0.290-67%
Usd Free Cash Flow To Equity Per Share---0.840-0.679-19%1.195-170%0.409-306%0.274-407%
Usd Market Cap504909136.000-25%628698554.000764270991.000-18%644778384.000-2%789603819.100-20%466705412.850+35%
Usd Price Per Share18.640-25%23.21028.215-18%23.790-2%29.148-20%17.228+35%
Usd Profit--3818000.000-12197000.000+419%24832250.000-85%-17214700.000+551%-11070925.000+390%
Usd Revenue--41673000.00037114750.000+12%73179750.000-43%25587500.000+63%14740050.000+183%
Usd Total Gains Per Share--0.121-0.168+239%1.240-90%0.417-71%0.218-44%
 EOD+3 -5MRQTTM+19 -14YOY+11 -215Y+16 -1710Y+18 -15

3.3 Fundamental Score

Let's check the fundamental score of Arcturus Therapeutics Holdings Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1533.061
Price to Book Ratio (EOD)Between0-11.928
Net Profit Margin (MRQ)Greater than00.092
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.849
Current Ratio (MRQ)Greater than14.763
Debt to Asset Ratio (MRQ)Less than10.294
Debt to Equity Ratio (MRQ)Less than10.415
Return on Equity (MRQ)Greater than0.150.015
Return on Assets (MRQ)Greater than0.050.010
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Arcturus Therapeutics Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.400
Ma 20Greater thanMa 5017.992
Ma 50Greater thanMa 10019.928
Ma 100Greater thanMa 20020.563
OpenGreater thanClose18.300
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-11-14 10:27:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Arcturus Therapeutics Holdings Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 9.2% means that $0.09 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 9.2%. The company is making a profit. +1
  • The TTM is -35.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ9.2%TTM-35.2%+44.4%
TTM-35.2%YOY-112.5%+77.2%
TTM-35.2%5Y-682.7%+647.5%
5Y-682.7%10Y-379.5%-303.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.2%-112.2%+121.4%
TTM-35.2%-221.4%+186.2%
YOY-112.5%-210.0%+97.5%
5Y-682.7%-342.2%-340.5%
10Y-379.5%-464.5%+85.0%
4.3.1.2. Return on Assets

Shows how efficient Arcturus Therapeutics Holdings Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • 1.0% Return on Assets means that Arcturus Therapeutics Holdings Inc generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 1.0%. Using its assets, the company is less efficient in making profit.
  • The TTM is -2.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.0%TTM-2.9%+4.0%
TTM-2.9%YOY5.3%-8.2%
TTM-2.9%5Y-5.9%+2.9%
5Y-5.9%10Y-8.6%+2.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0%-11.3%+12.3%
TTM-2.9%-11.7%+8.8%
YOY5.3%-11.3%+16.6%
5Y-5.9%-12.7%+6.8%
10Y-8.6%-14.1%+5.5%
4.3.1.3. Return on Equity

Shows how efficient Arcturus Therapeutics Holdings Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • 1.5% Return on Equity means Arcturus Therapeutics Holdings Inc generated $0.01 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 1.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -4.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.5%TTM-4.6%+6.1%
TTM-4.6%YOY8.7%-13.3%
TTM-4.6%5Y-12.3%+7.7%
5Y-12.3%10Y-16.4%+4.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5%-14.2%+15.7%
TTM-4.6%-15.9%+11.3%
YOY8.7%-14.3%+23.0%
5Y-12.3%-18.5%+6.2%
10Y-16.4%-19.3%+2.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Arcturus Therapeutics Holdings Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Arcturus Therapeutics Holdings Inc is operating .

  • Measures how much profit Arcturus Therapeutics Holdings Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-31.5%+31.5%
TTM-31.5%YOY-134.3%+102.8%
TTM-31.5%5Y-683.8%+652.2%
5Y-683.8%10Y-380.3%-303.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--222.9%+222.9%
TTM-31.5%-310.7%+279.2%
YOY-134.3%-223.5%+89.2%
5Y-683.8%-387.1%-296.7%
10Y-380.3%-498.5%+118.2%
4.3.2.2. Operating Ratio

Measures how efficient Arcturus Therapeutics Holdings Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.26 means that the operating costs are $1.26 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 1.258. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.369. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.258TTM1.369-0.112
TTM1.369YOY3.901-2.532
TTM1.3695Y13.716-12.347
5Y13.71610Y7.800+5.917
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2582.465-1.207
TTM1.3693.253-1.884
YOY3.9013.298+0.603
5Y13.7164.788+8.928
10Y7.8006.494+1.306
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Arcturus Therapeutics Holdings Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Arcturus Therapeutics Holdings Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.76 means the company has $4.76 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 4.763. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.129. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.763TTM4.129+0.633
TTM4.129YOY4.159-0.030
TTM4.1295Y4.911-0.782
5Y4.91110Y7.954-3.043
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.7633.637+1.126
TTM4.1293.890+0.239
YOY4.1594.666-0.507
5Y4.9115.953-1.042
10Y7.9546.277+1.677
4.4.3.2. Quick Ratio

Measures if Arcturus Therapeutics Holdings Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • A Quick Ratio of 3.85 means the company can pay off $3.85 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 3.849. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.727. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.849TTM3.727+0.123
TTM3.727YOY3.844-0.118
TTM3.7275Y4.728-1.002
5Y4.72810Y11.769-7.040
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8493.086+0.763
TTM3.7273.451+0.276
YOY3.8444.456-0.612
5Y4.7285.931-1.203
10Y11.7696.436+5.333
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Arcturus Therapeutics Holdings Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Arcturus Therapeutics Holdings Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Arcturus Therapeutics Holdings Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.29 means that Arcturus Therapeutics Holdings Inc assets are financed with 29.4% credit (debt) and the remaining percentage (100% - 29.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 0.294. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.337. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.294TTM0.337-0.044
TTM0.337YOY0.357-0.019
TTM0.3375Y0.391-0.054
5Y0.39110Y0.333+0.058
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2940.350-0.056
TTM0.3370.344-0.007
YOY0.3570.310+0.047
5Y0.3910.365+0.026
10Y0.3330.382-0.049
4.5.4.2. Debt to Equity Ratio

Measures if Arcturus Therapeutics Holdings Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 41.5% means that company has $0.42 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 0.415. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.512. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.415TTM0.512-0.096
TTM0.512YOY0.560-0.048
TTM0.5125Y0.792-0.280
5Y0.79210Y0.819-0.028
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4150.394+0.021
TTM0.5120.432+0.080
YOY0.5600.380+0.180
5Y0.7920.451+0.341
10Y0.8190.490+0.329
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Arcturus Therapeutics Holdings Inc generates.

  • Above 15 is considered overpriced but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • A PE ratio of 41.17 means the investor is paying $41.17 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The EOD is 33.061. Based on the earnings, the company is overpriced. -1
  • The MRQ is 41.167. Based on the earnings, the company is overpriced. -1
  • The TTM is -0.461. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD33.061MRQ41.167-8.106
MRQ41.167TTM-0.461+41.628
TTM-0.461YOY-3.335+2.874
TTM-0.4615Y-5.920+5.459
5Y-5.92010Y-8.862+2.942
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD33.061-2.303+35.364
MRQ41.167-2.403+43.570
TTM-0.461-3.148+2.687
YOY-3.335-3.251-0.084
5Y-5.920-6.084+0.164
10Y-8.862-6.764-2.098
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The EOD is -5.373. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.690. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -51.533. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.373MRQ-6.690+1.317
MRQ-6.690TTM-51.533+44.842
TTM-51.533YOY-1.262-50.271
TTM-51.5335Y-18.343-33.190
5Y-18.34310Y-13.132-5.210
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.373-3.042-2.331
MRQ-6.690-3.234-3.456
TTM-51.533-3.719-47.814
YOY-1.262-4.557+3.295
5Y-18.343-8.332-10.011
10Y-13.132-9.276-3.856
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Arcturus Therapeutics Holdings Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.40 means the investor is paying $2.40 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The EOD is 1.928. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.401. Based on the equity, the company is underpriced. +1
  • The TTM is 2.871. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.928MRQ2.401-0.473
MRQ2.401TTM2.871-0.470
TTM2.871YOY2.218+0.653
TTM2.8715Y4.958-2.088
5Y4.95810Y5.753-0.794
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.9281.943-0.015
MRQ2.4012.051+0.350
TTM2.8712.356+0.515
YOY2.2182.454-0.236
5Y4.9583.714+1.244
10Y5.7534.378+1.375
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Arcturus Therapeutics Holdings Inc.

4.8.1. Institutions holding Arcturus Therapeutics Holdings Inc

Institutions are holding 95.828% of the shares of Arcturus Therapeutics Holdings Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30Federated Hermes Inc17.33150.27094694060-1312-0.0279
2024-06-30BlackRock Inc9.78380.00152649838-93164-3.3964
2024-06-30ARK Investment Management LLC7.25510.4246196496427531516.2942
2024-06-30Morgan Stanley - Brokerage Accounts5.87760.00151591882-145012-8.3489
2024-06-30Nikko Asset Management Americas Inc5.77120.4383156306528654622.4475
2024-06-30Sumitomo Mitsui Trust Group Inc5.77120.0281156306528654622.4475
2024-06-30State Street Corp5.62630.00161523838-436098-22.2506
2024-06-30Vanguard Group Inc5.11280.00071384744-3150-0.227
2024-06-30Dimensional Fund Advisors, Inc.3.39030.0058918222-185598-16.8142
2024-06-30Woodline Partners LP2.7840.1753754023-160341-17.5358
2024-06-30FMR Inc2.05110.0009555524-66334-10.6671
2024-06-30Millennium Management LLC2.04930.0063555024396505250.1309
2024-06-30Geode Capital Management, LLC2.0160.0012546009-4254-0.7731
2024-06-30Portolan Capital Management, LLC1.79040.972348490724024898.1971
2024-06-30Goldman Sachs Group Inc1.6450.00184455418217122.6136
2024-06-30Wellington Management Company LLP1.3320.00163607497563426.5275
2024-06-30Jupiter Asset Management Limited1.30170.0811352550-9794-2.703
2024-06-30Granahan Investment Management Inc..1.27210.335734454984022.4995
2024-06-30Schonfeld Strategic Advisors LLC1.04640.0445283420-63074-18.2035
2024-06-30JPMorgan Chase & Co1.00430.0005272007-45544-14.3423
Total 84.21212.794222807981+437692+1.9%

4.9.2. Funds holding Arcturus Therapeutics Holdings Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Federated Hermes Kaufmann R8.99381.1079243588000
2024-09-30Federated Hermes Kaufmann Growth8.99381.1084243588000
2024-09-30Federated Hermes Kaufmann Small Cap A8.11561.2793219802000
2024-09-30Federated Hermes Kaufmann Small Cap Grow8.11561.2793219802000
2024-09-30ARK Genomic Revolution7.70493.643120867951443777.4328
2024-10-31ARK Genomic Revolution ETF7.69013.08312082785100250.4837
2024-09-30Nikko AM ARK Pstv Chg Innovt P JPY Acc7.51992.17212036696-35027-1.6907
2024-09-30Vanguard Total Stock Mkt Idx Inv2.67180.00172364000
2024-10-31SPDR® S&P Biotech ETF2.5890.176701203-10122-1.423
2024-10-31iShares Russell 2000 ETF2.19240.0155593781-1330-0.2235
2024-06-30UBS: US Equity Small Cap Growth1.6290.40944120600
2024-09-30Fidelity Select Biotechnology1.47440.187239933000
2024-09-30Vanguard Institutional Extnd Mkt Idx Tr1.43880.008338967859981.5633
2024-08-31Fidelity Small Cap Index0.8680.0182235096-5538-2.3014
2024-09-30JPM Thematics Genetic Thrps C2 Acc USD0.81120.8974219699-5458-2.4241
2024-10-31iShares Russell 2000 Growth ETF0.67360.027218244800
2024-10-31State St Russell Sm/Mid Cp® Indx NL Cl C0.6620.0071179302-5000-2.7129
2024-10-31iShares Biotechnology ETF0.64360.0439174324-1044-0.5953
2024-09-30DFA US Small Cap I0.58830.0221159343-2068-1.2812
2024-09-30Royce Micro Cap Trust0.57530.65231558032596719.9998
Total 73.951116.138420028929+120780+0.6%

5.3. Insider Transactions

Insiders are holding 8.458% of the shares of Arcturus Therapeutics Holdings Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-10-15Pad ChivukulaSELL1200020.76
2024-06-05Pad ChivukulaSELL11445
2024-06-03Pad ChivukulaSELL2600040.01
2024-03-25Pad ChivukulaSELL1743535.02
2024-03-19Pad ChivukulaSELL856535.01
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Net Income  -16,2227,649-8,573-18,244-26,8179,601-17,21621,0343,818



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets370,654
Total Liabilities108,788
Total Stockholder Equity261,866
 As reported
Total Liabilities 108,788
Total Stockholder Equity+ 261,866
Total Assets = 370,654

Assets

Total Assets370,654
Total Current Assets330,821
Long-term Assets39,833
Total Current Assets
Cash And Cash Equivalents 237,178
Net Receivables 30,199
Other Current Assets 63,444
Total Current Assets  (as reported)330,821
Total Current Assets  (calculated)330,821
+/-0
Long-term Assets
Property Plant Equipment 37,948
Long-term Assets Other 1,885
Long-term Assets  (as reported)39,833
Long-term Assets  (calculated)39,833
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities69,463
Long-term Liabilities39,325
Total Stockholder Equity261,866
Total Current Liabilities
Accounts payable 10,131
Other Current Liabilities 32,396
Total Current Liabilities  (as reported)69,463
Total Current Liabilities  (calculated)42,527
+/- 26,936
Long-term Liabilities
Long-term Liabilities  (as reported)39,325
Long-term Liabilities  (calculated)0
+/- 39,325
Total Stockholder Equity
Common Stock27
Retained Earnings -418,802
Other Stockholders Equity 680,641
Total Stockholder Equity (as reported)261,866
Total Stockholder Equity (calculated)261,866
+/-0
Other
Cash and Short Term Investments 237,178
Common Stock Shares Outstanding 27,062
Current Deferred Revenue26,936
Liabilities and Stockholders Equity 370,654
Net Debt -211,191
Net Working Capital 261,358
Short Long Term Debt Total 25,987



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-30
> Total Assets 
0
0
201
0
21,704
19,805
50,324
45,603
40,171
30,863
22,318
0
41,624
37,647
71,683
67,097
62,689
55,912
51,568
46,419
42,351
40,586
52,024
0
44,322
37,115
44,198
44,419
70,940
87,215
82,143
72,104
149,935
322,520
476,456
481,468
448,813
434,536
392,814
341,988
337,014
293,627
450,387
470,863
430,646
457,650
429,402
418,849
388,608
370,654
370,654388,608418,849429,402457,650430,646470,863450,387293,627337,014341,988392,814434,536448,813481,468476,456322,520149,93572,10482,14387,21570,94044,41944,19837,11544,322052,02440,58642,35146,41951,56855,91262,68967,09771,68337,64741,624022,31830,86340,17145,60350,32419,80521,704020100
   > Total Current Assets 
0
0
180
0
21,680
19,722
50,218
45,416
39,959
30,652
22,126
0
41,427
37,363
52,346
54,764
54,358
52,626
51,299
46,173
42,121
40,406
50,868
48,573
41,682
34,401
41,828
36,606
63,338
79,408
74,290
63,759
142,000
314,100
467,789
469,996
438,038
420,966
378,961
327,005
291,505
246,680
403,333
424,555
385,244
393,268
386,590
375,788
347,008
330,821
330,821347,008375,788386,590393,268385,244424,555403,333246,680291,505327,005378,961420,966438,038469,996467,789314,100142,00063,75974,29079,40863,33836,60641,82834,40141,68248,57350,86840,40642,12146,17351,29952,62654,35854,76452,34637,36341,427022,12630,65239,95945,41650,21819,72221,680018000
       Cash And Cash Equivalents 
0
0
97
0
17,593
4,540
22,095
10,392
6,912
2,714
2,176
0
8,570
9,970
16,658
13,487
15,093
4,375
2,304
4,674
3,568
3,007
24,965
-48,573
39,777
30,331
36,709
31,220
55,840
74,172
71,353
59,471
136,111
307,023
462,895
466,839
433,574
413,880
370,492
319,678
283,491
237,676
391,883
327,935
323,471
311,918
347,005
288,396
315,329
237,178
237,178315,329288,396347,005311,918323,471327,935391,883237,676283,491319,678370,492413,880433,574466,839462,895307,023136,11159,47171,35374,17255,84031,22036,70930,33139,777-48,57324,9653,0073,5684,6742,3044,37515,09313,48716,6589,9708,57002,1762,7146,91210,39222,0954,54017,59309700
       Short-term Investments 
0
0
0
0
4,000
15,000
28,008
34,033
32,025
26,724
19,522
0
32,523
25,537
34,022
39,739
37,989
46,972
47,938
40,578
37,620
36,814
23,608
97,146
10,455
2,499
0
0
0
0
0
0
0
0
0
1,248
920
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000009201,2480000000002,49910,45597,14623,60836,81437,62040,57847,93846,97237,98939,73934,02225,53732,523019,52226,72432,02534,03328,00815,0004,0000000
       Net Receivables 
0
0
10
0
87
182
46
991
1,022
0
117
0
0
0
116
0
0
0
521
0
0
0
480
0
1,371
1,123
4,481
4,457
5,817
2,625
2,179
2,351
2,829
2,447
2,125
2,007
2,163
2,015
3,367
3,691
2,247
2,044
2,764
92,483
2,799
38,220
32,064
27,057
24,085
30,199
30,19924,08527,05732,06438,2202,79992,4832,7642,0442,2473,6913,3672,0152,1632,0072,1252,4472,8292,3512,1792,6255,8174,4574,4811,1231,371048000052100011600011701,022991461828701000
       Other Current Assets 
0
0
73
0
87
182
115
991
1,022
1,214
311
0
334
1,856
1,666
1,538
1,276
1,279
1,057
921
933
585
355
0
534
193
638
122
22
2,611
758
1,937
3,060
4,630
2,769
1,150
2,301
5,071
5,102
3,636
5,767
6,960
8,686
4,137
3,974
8,130
7,521
5,335
7,594
63,444
63,4447,5945,3357,5218,1303,9744,1378,6866,9605,7673,6365,1025,0712,3011,1502,7694,6303,0601,9377582,6112212263819353403555859339211,0571,2791,2761,5381,6661,85633403111,2141,0229911151828707300
   > Long-term Assets 
0
0
21
0
24
83
106
187
212
211
192
0
197
284
19,337
12,333
8,331
3,286
269
246
230
180
1,156
-48,573
2,640
2,714
2,370
7,813
7,602
7,807
7,853
8,345
7,935
8,420
8,667
11,472
10,775
13,570
13,853
14,983
45,509
46,947
47,054
46,308
45,402
64,382
42,812
43,061
41,600
39,833
39,83341,60043,06142,81264,38245,40246,30847,05446,94745,50914,98313,85313,57010,77511,4728,6678,4207,9358,3457,8537,8077,6027,8132,3702,7142,640-48,5731,1561802302462693,2868,33112,33319,3372841970192211212187106832402100
       Property Plant Equipment 
0
0
18
0
17
32
49
93
105
107
97
0
112
197
227
235
219
212
240
219
210
167
1,049
0
1,943
2,064
1,975
7,706
7,495
7,397
7,483
8,138
7,828
8,313
8,560
10,117
9,748
10,826
11,261
12,775
43,431
44,866
44,960
44,192
43,275
42,249
40,927
41,176
39,715
37,948
37,94839,71541,17640,92742,24943,27544,19244,96044,86643,43112,77511,26110,8269,74810,1178,5608,3137,8288,1387,4837,3977,4957,7061,9752,0641,94301,0491672102192402122192352271971120971071059349321701800
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
590
543
288
0
0
303
263
100
0
0
0
1,248
920
670
515
131
0
0
0
0
0
0
0
0
0
0
00000000001315156709201,24800010026330300288543590000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
70
27
20
13
107
0
107
107
107
107
107
107
107
107
107
107
5,289
107
107
2,074
2,077
2,077
2,078
2,081
0
0
2,127
0
0
0
0
0
000002,127002,0812,0782,0772,0772,0741071075,289107107107107107107107107107107010713202770000000000000000000
> Total Liabilities 
0
0
768
0
343
1,281
1,636
3,346
4,753
4,905
2,375
0
2,864
2,564
2,352
2,110
2,907
3,295
4,340
2,190
1,657
2,296
18,230
0
26,527
22,964
30,556
38,065
49,322
51,320
56,351
55,122
56,512
60,890
79,903
128,861
143,165
175,410
164,603
157,239
166,297
147,960
180,075
141,615
145,471
177,588
150,889
154,877
130,025
108,788
108,788130,025154,877150,889177,588145,471141,615180,075147,960166,297157,239164,603175,410143,165128,86179,90360,89056,51255,12256,35151,32049,32238,06530,55622,96426,527018,2302,2961,6572,1904,3403,2952,9072,1102,3522,5642,86402,3754,9054,7533,3461,6361,281343076800
   > Total Current Liabilities 
0
0
768
0
343
1,281
1,636
3,346
4,753
4,905
2,375
0
2,864
2,564
2,352
2,110
2,907
3,295
4,340
2,190
1,657
2,296
11,040
0
18,253
13,600
12,577
14,612
16,414
21,688
21,324
21,650
23,046
28,014
49,521
53,333
70,769
118,239
99,537
107,306
92,743
75,849
126,984
90,130
90,345
87,683
81,989
115,430
91,717
69,463
69,46391,717115,43081,98987,68390,34590,130126,98475,84992,743107,30699,537118,23970,76953,33349,52128,01423,04621,65021,32421,68816,41414,61212,57713,60018,253011,0402,2961,6572,1904,3403,2952,9072,1102,3522,5642,86402,3754,9054,7533,3461,6361,281343076800
       Short-term Debt 
0
0
662
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
133
133
0
0
0
0
11,168
0
0
750
775
801
827
1,474
1,337
1,198
2,880
4,568
6,430
19,965
22,474
25,913
30,435
31,485
60,655
3,987
4,092
4,200
4,309
4,270
3,917
0
03,9174,2704,3094,2004,0923,98760,65531,48530,43525,91322,47419,9656,4304,5682,8801,1981,3371,4748278017757500011,168000013313300000000000000066200
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
133
133
0
0
0
0
0
0
0
750
0
0
0
0
0
0
1,250
3,125
5,000
18,482
22,474
24,260
27,018
27,702
60,655
0
0
0
0
0
0
0
000000060,65527,70227,01824,26022,47418,4825,0003,1251,2500000007500000000133133000000000000000000
       Accounts payable 
0
0
23
0
67
31
47
1,409
1,457
1,532
305
0
161
527
57
111
138
152
528
488
19
36
1,790
0
2,781
2,905
2,398
4,118
3,187
4,013
5,793
3,779
4,395
6,478
10,774
5,597
10,084
8,265
10,058
10,014
5,762
17,962
7,449
19,344
13,619
18,362
5,279
9,144
13,905
10,131
10,13113,9059,1445,27918,36213,61919,3447,44917,9625,76210,01410,0588,26510,0845,59710,7746,4784,3953,7795,7934,0133,1874,1182,3982,9052,78101,79036194885281521381115752716103051,5321,4571,40947316702300
       Other Current Liabilities 
0
0
83
0
276
1,250
1,589
1,937
3,296
3,373
2,070
0
2,703
2,037
2,295
1,999
2,769
3,143
3,812
1,702
1,638
2,260
2,793
0
15,472
2,244
3,907
2,016
2,722
5,875
6,307
8,301
10,546
14,640
17,759
25,232
36,184
32,393
23,523
18,317
30,197
15,850
30,232
28,306
20,678
24,353
25,058
27,507
29,019
32,396
32,39629,01927,50725,05824,35320,67828,30630,23215,85030,19718,31723,52332,39336,18425,23217,75914,64010,5468,3016,3075,8752,7222,0163,9072,24415,47202,7932,2601,6381,7023,8123,1432,7691,9992,2952,0372,70302,0703,3733,2961,9371,5891,25027608300
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,190
0
8,274
9,364
17,979
23,453
32,908
29,632
35,027
33,472
33,466
32,876
30,382
75,528
72,396
57,171
65,066
49,933
73,554
72,111
53,091
51,485
55,126
89,905
68,900
39,447
38,308
39,325
39,32538,30839,44768,90089,90555,12651,48553,09172,11173,55449,93365,06657,17172,39675,52830,38232,87633,46633,47235,02729,63232,90823,45317,9799,3648,27407,1900000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,911
9,945
9,980
10,016
14,995
15,028
15,059
15,076
13,845
58,147
56,309
42,345
40,633
39,235
35,761
32,038
0
0
0
0
0
0
0
0
0000000032,03835,76139,23540,63342,34556,30958,14713,84515,07615,05915,02814,99510,0169,9809,9459,91100000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,425
0
0
0
7,190
0
8,274
9,364
8,068
8,025
17,652
14,551
15,182
13,815
14,013
13,645
12,512
11,671
10,728
9,891
19,931
6,641
5,590
8,855
22,875
0
27,015
0
0
0
0
0
0000027,015022,8758,8555,5906,64119,9319,89110,72811,67112,51213,64514,01313,81515,18214,55117,6528,0258,0689,3648,27407,1900003,425000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,652
14,551
15,182
13,815
14,013
13,645
12,512
11,313
9,850
8,497
19,931
6,641
5,590
5,179
0
20,569
0
0
0
0
0
0
00000020,56905,1795,5906,64119,9318,4979,85011,31312,51213,64514,01313,81515,18214,55117,6520000000000000000000000000000
> Total Stockholder Equity
0
0
-567
0
21,361
18,524
48,688
42,257
35,418
25,958
19,943
0
38,760
35,083
69,331
64,987
59,782
52,617
47,228
44,229
40,694
38,290
33,794
33,794
17,795
14,151
13,642
6,354
21,618
35,895
25,792
16,982
93,423
261,630
396,553
352,607
305,648
259,126
228,211
184,749
170,717
145,667
270,312
329,248
285,175
280,062
278,513
263,972
258,583
261,866
261,866258,583263,972278,513280,062285,175329,248270,312145,667170,717184,749228,211259,126305,648352,607396,553261,63093,42316,98225,79235,89521,6186,35413,64214,15117,79533,79433,79438,29040,69444,22947,22852,61759,78264,98769,33135,08338,760019,94325,95835,41842,25748,68818,52421,3610-56700
   Common Stock
0
0
4
0
32
32
39
39
39
39
39
0
58
58
74
74
74
74
74
74
74
74
212
0
214
214
214
214
13
15
15
15
21
25
26
26
26
26
26
26
26
26
27
27
27
27
27
27
27
27
272727272727272726262626262626262521151515132142142142140212747474747474747458580393939393932320400
   Retained Earnings Total Equity000000-287,3870-455,488-420,222-398,659-347,490-308,827-254,743-200,162-143,816-112,712-91,708-81,445-71,668-60,679-53,2460000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-22
0
0
0
-30
0
0
0
-60
0
0
0
-111
0
5
-3
-6
-4
-3
-2
-3
33,794
2
4
-1,497
-1,669
-1,846
-2,028
-2,181
-2,363
-2,575
-2,794
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000-2,794-2,575-2,363-2,181-2,028-1,846-1,669-1,4974233,794-3-2-3-4-6-350-111000-60000-30000-2200
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
58,302
58,701
74,851
96,559
97,445
98,412
185,110
374,317
540,343
552,743
560,365
567,927
575,675
583,382
590,913
601,129
0
616,608
0
0
0
0
0
0
000000616,6080601,129590,913583,382575,675567,927560,365552,743540,343374,317185,11098,41297,44596,55974,85158,70158,30200000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
7,637
0
31,231
31,523
67,413
68,718
69,659
70,685
71,532
0
100,570
101,155
140,385
141,016
141,594
142,239
142,780
143,299
143,454
143,604
56,674
0
57,189
57,796
58,302
60,370
76,697
98,587
99,626
100,775
187,685
377,111
540,343
552,743
560,365
567,927
575,675
583,382
590,913
601,129
608,426
616,608
625,085
636,194
646,352
658,628
670,455
680,641
680,641670,455658,628646,352636,194625,085616,608608,426601,129590,913583,382575,675567,927560,365552,743540,343377,111187,685100,77599,62698,58776,69760,37058,30257,79657,189056,674143,604143,454143,299142,780142,239141,594141,016140,385101,155100,570071,53270,68569,65968,71867,41331,52331,23107,63700



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.